Acceleron Pharma Reports Positive Topline Results From PULSAR Trial

By RTTNews Staff Writer ✉ | Published: 1/27/2020 5:24 PM ET

Acceleron Pharma Inc. (XLRN) announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial
hypertension. In the trial, sotatercept showed a statistically significant reduction in pulmonary vascular resistance, the trial's primary endpoint, at week 24 versus placebo.

The company plans to present a detailed review of the topline results from the
PULSAR Phase 2 trial of sotatercept at a medical conference later in the current year.

Shares of Acceleron Pharma Inc. were up nearly 70% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks PDUFA COVID 19 Vaccines peanut allergy Trelegy Ellipta Pain drug exertional heatstroke allergic conjunctivitis

Biotech Stocks Facing FDA Decision In August 2020

New Drugs Approved In June

Coronavirus Vaccines In Human Trials COVID19 Antibodies Spike Protein US Operation Warp Speed

Tracking Coronavirus Vaccines In Human Trials

Editors Pick

Berkshire Q2 Profit Up 87%, But Operating Profit Down 10%

Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent.

Twitter In Preliminary Talks To Buy TikTok's U.S. Operations : Report

Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok.

Pfizer Signs Deal To Boost Supply Of Gilead's Remdesivir For COVID-19 Patients

Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.